--- title: "Analyze JingTai Technology using deepseek R1 + Search:" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/26794317.md" description: "$XTALPI(02228.HK) The information about deepseek has been explosive these days. Today, I tried to use its R1+Search combination to see the effect, which just happens to target the investment opportunity I am most concerned about, XTALPI Technology: Prompt: Evaluate the financial and business competitiveness of a Hong Kong-listed company: XTALPI Technology. Btw: I think this Prompt is too simple. But better than nothing. Friends who are interested can consider a more precise Prompt..." datetime: "2025-01-26T08:38:35.000Z" locales: - [en](https://longbridge.com/en/topics/26794317.md) - [zh-CN](https://longbridge.com/zh-CN/topics/26794317.md) - [zh-HK](https://longbridge.com/zh-HK/topics/26794317.md) author: "[老板的老板 AI Exec](https://longbridge.com/en/profiles/123.md)" --- # Analyze JingTai Technology using deepseek R1 + Search: $XTALPI(02228.HK) Information about Deepseek has exploded in the past few days. Today, I will try to use its R1+Search combination to see the effect, which just happens to target the investment opportunity I am most concerned about, XTALPI Technology: Prompt: Evaluate the financial and business competitiveness of a Hong Kong-listed company: XTALPI Technology. _btw: I think this prompt is too simple. But better than nothing. Friends who are interested can consider a more precise prompt._ * * * ### **XTALPI Technology (02228.HK) Financial and Business Competitiveness Assessment** The following is a comprehensive analysis of XTALPI Technology from five dimensions: financial health, business model, technological barriers, market position, and risks, combined with its performance after listing in 2024 and industry trends, citing the latest data and strategic dynamics. * * * #### **1\. Financial Health (High short-term risk, long-term reliance on financing)** **Revenue and Loss**: - Revenue from 2021 to 2023 was 63 million, 133 million, and 174 million yuan, with a compound annual growth rate of about 66%, but the growth rate is slowing (only a 30% year-on-year increase in 2023). - **Losses continue to expand**: In 2023, operating losses were 722 million yuan, with total losses of 1.9 billion yuan for the year, and adjusted losses of 522 million yuan. The loss rate (loss/revenue) reached 297%, far exceeding the industry average. - **Cash Reserves**: As of the end of 2023, cash and cash equivalents were 710 million yuan, which, at the current loss rate, is expected to support operations for only 1-2 years, requiring reliance on subsequent financing or business self-sustainability. **Financing and Valuation**: - In June 2024, the net fundraising amount from the Hong Kong stock listing was 1.043 billion HKD, with cornerstone investors including Henderson Land's Li Ka-shing, Tencent, Sequoia, etc., alleviating short-term liquidity pressure. - The current market value is approximately 18.2 billion HKD (January 2025), with a price-to-sales ratio (PS) exceeding 100 times, reflecting the market's high expectations for its technology premium, but the high valuation needs to be supported by explosive revenue growth in the future. **Financial Score**: **3/5** (Significant revenue growth, but severe losses and reliance on financing). * * * #### **2\. Business Model (Technology-driven, multi-field synergy)** **Core Business**: - **AI Drug Development**: Covers small molecule and large molecule drug discovery, with a $250 million collaboration with Eli Lilly in 2023, validating its technology commercialization capability. - **Intelligent Automated Laboratories**: Robotic laboratory clusters + AI algorithms, shortening the R&D cycle (for example, Pfizer's PAXLOVID crystal form prediction project saved several months) - **Future Chemistry and New Materials**: Utilizing chemical synthesis data to build models, expanding into energy, agriculture, and other fields, with a commercialization cycle shorter than drug development. **Revenue Structure**: - Drug discovery solutions (approximately 60%), intelligent automation services (40%), with clients including 16 of the top 20 global pharmaceutical companies (such as Pfizer and Eli Lilly). **Business Model Rating**: **4/5** (high degree of technology integration, but high revenue concentration). * * * #### **III. Technical Barriers (Globally Leading, Patent Moat)** **Technology Portfolio**: - Quantum physics computing + AI algorithms + robotic automation, forming a "compute-predict-experimental validation" closed loop, reducing R&D trial and error costs. - Over 160 authorized patents covering underlying technologies such as polymorph prediction and free energy calculation. **R&D Capability**: - A team of over 500 scientists (including a core team with MIT backgrounds), with global R&D centers in Shenzhen, Beijing, Boston, etc., and laboratory space exceeding 10,000 square meters. **Technology Rating**: **4.5/5** (significant technological differentiation, but requires continuous investment to maintain leadership). * * * #### **IV. Market Position and Industry Trends (Track Leader, Benefiting from AI Pharmaceutical Dividends)** **Industry Opportunities**: - **Rapid Growth of AI Pharmaceuticals**: The global market size is expected to exceed $5 billion by 2025, with Jingta Technology being the only pure AI pharmaceutical stock in Hong Kong, highlighting its rarity. - **Policy Support**: Hong Kong's 18C listing rules attract unprofitable tech companies, with Jingta being the first 18C new stock to receive policy endorsement. **Competitive Landscape**: - International competitors: Schrödinger (US stock), Exscientia (US stock); domestic competitors: Yingsi Intelligent, Weizhi Jun Biotechnology. Jingta currently holds a leading position due to its full-chain technology layout and deep cooperation with pharmaceutical companies. **Market Position Rating**: **4/5** (leading position is beginning to emerge, but competition in the track is intensifying). * * * #### **V. Risk Warning** 1. **Profitability Uncertainty**: Continuous expansion of losses, revenue from commercialization projects needs to accelerate realization. 2. **Technology Iteration Risk**: AI algorithms rely on data quality; breakthroughs by competitors may weaken advantages. 3. **Geopolitical Factors**: Sino-US technology competition may affect international client cooperation (e.g., orders from US pharmaceutical companies). * * * ### **Comprehensive Rating: 3.8/5** - **Strengths**: Globally leading technology, solid cooperation with pharmaceutical companies, high growth potential in the track. - **Weaknesses**: Significant financial pressure, profitability model yet to be validated, risk of valuation bubble. - **Outlook**: If the AI drug pipeline commercializes by 2025 (e.g., projects in collaboration with Eli Lilly), it may drive a revenue inflection point; conversely, continued losses may trigger a valuation adjustment. **Investment Advice**: Long-term focus on technology conversion efficiency, short-term caution towards high volatility ### Related Stocks - [02228.HK](https://longbridge.com/en/quote/02228.HK.md) ## Comments (7) - **东方顺 · 2025-01-26T13:29:02.000Z**: It seems those who rest are not the bosses, bosses work anytime. - **老板的老板 AI Exec** (2025-01-26T13:38:49.000Z): Those who rest have been fired. What the hell is this time? Those who don't work hard to earn money will all be eliminated. The boss is ruthless. - **momo的交易员** (2025-01-26T14:48:41.000Z): You are so heartless - **老板的老板 AI Exec** (2025-01-26T15:00:22.000Z): If Heaven has feelings, Heaven too grows old; I only fear waiting becomes too long. - **赔中学 · 2025-01-26T08:43:35.000Z**: Is the boss not taking a break today either? - **老板的老板 AI Exec** (2025-01-26T09:09:31.000Z): To make big money. I dragged a bunch of people to work with me. Including my analysts. 😄 - **贴贴** (2025-01-26T12:09:47.000Z): Happy New Year, boss